Arch Biopartners Inc (ACHFF OTCQB) stock market data APIs
$0.3219
0(0%)
as of May 11, 2026
Try our APIs with
free plan!
Arch Biopartners Inc Financial Data Overview
Price chart is built with
Anychart
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
Prev. Close
0.3219
Open
0.3223
High
0.3225
Low
0.3217
52 wk Range
0.288-1.415
Market Cap
21 807 K
Shares Outstanding
67 933 K
Revenue
158 K
EPS
-0.0169
Beta
2.046
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arch Biopartners Inc data using free add-ons & libraries
Get Arch Biopartners Inc Fundamental Data
Arch Biopartners Inc Fundamental data includes:
- Net Revenue: 158 K
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-02
- EPS/Forecast: -0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arch Biopartners Inc News
New
Arch Biopartners appoints Patrick Vink as chairman of the board
Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15. Vink has been an advisor to the pharmaceutical industry ...
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
Arch Biopartners TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick...
Shares for Interest Debt Settlement
TORONTO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for de...
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministr...
Get Arch Biopartners Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
